SR One, a biotechnology venture capital firm, led a $200m Series C round in Zenas BioPharma, a global biopharmaceutical company, with participation from NEA, Norwest Venture Partners, Delos Capital, Enavate Sciences, Longitude Capital, Federated Hermes Kaufmann Funds, Arrowmark Partners, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital. “We are pleased and appreciative of the support we have received from this group of tremendous life sciences investors as we advance the ongoing obexelimab development program across multiple auto-immune diseases. Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world. This financing enables us to complete multiple potentially value driving clinical programs,” Lonnie Moulder, Zenas BioPharma Founder and CEO.